Velphoro® receives EU marketing authorisation for treatment of hyperphosphatemia in adult CKD patients on dialysis
Velphoro® (sucroferric oxyhydroxide) has received EU marketing authorisation from the European Commission for the contro…
Velphoro® (sucroferric oxyhydroxide) has received EU marketing authorisation from the European Commission for the contro…
. - Velphoro® (PA21) recommended for approval in the European Union for the treatment of hyperphosphatemia in adult Chr…
Velphoro® (sucroferric oxyhydroxide) has received US Food and Drug Administration (FDA) approval for the control of seru…
Results of a new clinical study show that a single 1,000 mg dose of the intravenous iron treatment Ferinject® rapidly im…
Data from two large, multi-center, randomised, controlled clinical trials of Injectafer® (US brand name of Ferinject®, f…